Blomjous E C, Schipper N W, Baak J P, Vos W, De Voogt H J, Meijer C J
Department of Pathology, Free University Hospital, The Netherlands.
Am J Clin Pathol. 1989 Mar;91(3):243-8. doi: 10.1093/ajcp/91.3.243.
In 80 patients with primary superficial bladder carcinoma Tumor Nodes Metastasis (TNM classification: stages Ta and T1) with adequate follow-up of at least four years, the value of selective nuclear morphometry and DNA flow cytometry on paraffin-embedded material in addition to classic prognosticators was assessed. Only the quantitative techniques appeared to be valuable predictors of new tumor occurrence. The recurrence rate in patients with large nuclei (mean nuclear area greater than 95 micron 2; n = 29) and in aneuploid cases (n = 30) was significantly higher (Wilcoxon: P = 0.05 and P = 0.0001) than in those with small nuclei (mean nuclear area less than = 95 micron 2; n = 51) and diploid cases (n = 50). The prevalence of large nuclei and aneuploidy also appeared useful to predict progressive recurrence, i.e., grade 3 or/and muscle invasive carcinoma (TNM classification: stages T2-T4) (chi-square: P less than 0.0001). Clinical follow-up showed that only 62.1% of the cases with large nuclei remained free of progressive recurrence, compared with 92.2% of those with small nuclei (Mantel-Cox: P less than 0.0001). For the aneuploid and diploid cases, these figures came to 53.3% and 98% (Mantel-Cox: P less than 0.0001). By multivariate analysis DNA ploidy was selected as the best discriminator. None of the classic prognosticators, including histologic grade, had additional prognostic value. Also, morphometry did not add to the prognosis prediction, which can be explained by the considerable overlapping between the prevalence of large nuclei and aneuploidy (24 of 29 and 30 cases, respectively). These findings practically suggest that patients presenting with superficial carcinoma with large nuclei (mean nuclear area greater than 95 microns 2) or aneuploid DNA values should be treated more aggressively.
在80例原发性浅表性膀胱癌患者中(肿瘤-淋巴结-转移分期:Ta期和T1期),这些患者均有至少四年的充分随访,我们评估了除经典预后指标外,选择性核形态计量学和石蜡包埋材料的DNA流式细胞术的价值。只有定量技术似乎是新肿瘤发生的有价值预测指标。大细胞核(平均核面积大于95平方微米;n = 29)患者和非整倍体病例(n = 30)的复发率显著高于小细胞核(平均核面积小于或等于95平方微米;n = 51)患者和二倍体病例(n = 50)(Wilcoxon检验:P = 0.05和P = 0.0001)。大细胞核和非整倍体的发生率对于预测进展性复发(即3级或/和肌层浸润性癌,肿瘤-淋巴结-转移分期:T2-T4期)似乎也很有用(卡方检验:P小于0.0001)。临床随访显示,大细胞核病例中只有62.1%无进展性复发,而小细胞核病例为92.2%(Mantel-Cox检验:P小于0.0001)。对于非整倍体和二倍体病例,这些数字分别为53.3%和98%(Mantel-Cox检验:P小于0.0001)。通过多变量分析,DNA倍性被选为最佳鉴别指标。包括组织学分级在内的所有经典预后指标均无额外的预后价值。此外,形态计量学对预后预测没有帮助,这可以通过大细胞核和非整倍体发生率之间的大量重叠(分别为29例和30例中的24例)来解释。这些发现实际上表明,患有大细胞核(平均核面积大于95平方微米)或非整倍体DNA值的浅表性癌患者应接受更积极的治疗。